| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology and Genetics |
Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107 [T. K., F. T., S. Y., A. M., H. A., C. M. C.], and Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania 19104 [N. N. W., L. R. K.]
The aim of this study was to evaluate the promoter methylation status and loss of heterozygosity (LOH) of the SEMA3B in non-small cell lung cancers (NSCLCs). We analyzed the methylation status of semaphorin 3B (SEMA3B) promoter and LOH at 3p21.3 in eight NSCLC cell lines and 27 primary tumors. Hypermethylation of SEMA3B was found in 50% of the cell lines and 41% of the primary tumors studied. The presence of hypermethylation was statistically associated with loss of SEMA3B expression in both cell lines (P = 0.02) and primary tumors (P < 0.01). There was no correlation between SEMA3B and tumor stage. On the other hand, the correlation between SEMA3B methylation status and LOH at 3p21.3 was significant (P = 0.02). Notably, 7 of 8 tumors with both hypermethylation and LOH of SEMA3B showed the absence of the expression. Treatment with 5-AZAC restored SEMA3B expression in NSCLC cell line. These results indicate that SEMA3B gene alterations may play a important role in the malignant transformation of NSCLC via a two-hit mechanism, including epigenetic changes and allelic loss, for tumor suppressor gene inactivation.
This article has been cited by other articles:
|
|
 |
|
  L. Capparuccia and L. Tamagnone Semaphorin signaling in cancer cells and in cells of the tumor microenvironment - two sides of a coin J. Cell Sci., June 1, 2009; 122(11): 1723 - 1736. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bernal, F. Aguayo, C. Villarroel, M. Vargas, I. Diaz, F. J. Ossandon, E. Santibanez, M. Palma, E. Aravena, C. Barrientos, et al. Reprimo as a Potential Biomarker for Early Detection in Gastric Cancer Clin. Cancer Res., October 1, 2008; 14(19): 6264 - 6269. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Varshavsky, O. Kessler, S. Abramovitch, B. Kigel, S. Zaffryar, G. Akiri, and G. Neufeld Semaphorin-3B Is an Angiogenesis Inhibitor That Is Inactivated by Furin-Like Pro-Protein Convertases Cancer Res., September 1, 2008; 68(17): 6922 - 6931. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Rolny, L. Capparuccia, A. Casazza, M. Mazzone, A. Vallario, A. Cignetti, E. Medico, P. Carmeliet, P. M. Comoglio, and L. Tamagnone The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment J. Exp. Med., May 12, 2008; 205(5): 1155 - 1171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Yang, C. M. Kiernan, Y. Tian, H. R. Salwen, A. Chlenski, B. A. Brumback, W. B. London, and S. L. Cohn Methylation of CASP8, DCR2, and HIN-1 in Neuroblastoma Is Associated with Poor Outcome Clin. Cancer Res., June 1, 2007; 13(11): 3191 - 3197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Angeloni Molecular analysis of deletions in human chromosome 3p21 and the role of resident cancer genes in disease Brief Funct Genomic Proteomic, May 24, 2007; (2007) elm007v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Taniguchi, T. Masuda, M. Fukaya, H. Kataoka, M. Mishina, H. Yaginuma, M. Watanabe, and T. Shimizu Identification and characterization of a novel member of murine semaphorin family Genes Cells, August 1, 2005; 10(8): 785 - 792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Marsit, J. K. Wiencke, M. Liu, and K. T. Kelsey The race associated allele of Semaphorin 3B (SEMA3B) T415I and its role in lung cancer in African-Americans and Latino-Americans Carcinogenesis, August 1, 2005; 26(8): 1446 - 1449. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Zucchi, E. Mento, V. A. Kuznetsov, M. Scotti, V. Valsecchi, B. Simionati, E. Vicinanza, G. Valle, S. Pilotti, R. Reinbold, et al. Gene expression profiles of epithelial cells microscopically isolated from a breast-invasive ductal carcinoma and a nodal metastasis PNAS, December 28, 2004; 101(52): 18147 - 18152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Marsit, M. Hasegawa, T. Hirao, D.-H. Kim, K. Aldape, P. W. Hinds, J. K. Wiencke, H. H. Nelson, and K. T. Kelsey Loss of Heterozygosity of Chromosome 3p21 Is Associated with Mutant TP53 and Better Patient Survival in Non-Small-Cell Lung Cancer Cancer Res., December 1, 2004; 64(23): 8702 - 8707. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Wan, Y. Gong, W. Qin, P. Zhang, J. Li, L. Wei, X. Zhou, H. Li, X. Qiu, F. Zhong, et al. Large-scale cDNA transfection screening for genes related to cancer development and progression PNAS, November 2, 2004; 101(44): 15724 - 15729. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Castro-Rivera, S. Ran, P. Thorpe, and J. D. Minna Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect PNAS, August 3, 2004; 101(31): 11432 - 11437. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Suzuki, N. Sunaga, D. S. Shames, S. Toyooka, A. F. Gazdar, and J. D. Minna RNA Interference-Mediated Knockdown of DNA Methyltransferase 1 Leads to Promoter Demethylation and Gene Re-Expression in Human Lung and Breast Cancer Cells Cancer Res., May 1, 2004; 64(9): 3137 - 3143. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
